Clinical trials for the development of orphan medicinal products as defined in Regulation (EC) No 141/2000 of the European Parliament and of the Council [Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (OJ L 18, 22.1.2000, p. 1).] and of medicinal products addressed to subjects affected by severe, debilitating and often life-threatening diseases affecting no more than one person in 50000 in the Union (ultra-rare diseases) should be fostered.
Recital 9, Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…
In forcesince 16 Apr 2014